Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Explore the Innovation Trends Shaping Tomorrow’s Investment Landscape (click to learn more) Sekur Private Data Advances Defense-Grade Secure Communications Platform (click to learn more) Sorrento Resources Ltd. Intersects 33m of 2.12% TREO, Bottom Brook, Newfoundland (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Novocure Ltd NVCR

Healthcare Medical Devices
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating... see more

Recent & Breaking News (NDAQ:NVCR)

Novocure Reports First Quarter 2026 Financial Results

Business Wire April 30, 2026

Novocure to Report First Quarter 2026 Financial Results

Business Wire April 1, 2026

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

Business Wire March 26, 2026

Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer

Business Wire March 2, 2026

Novocure to Participate in 2026 Leerink Global Healthcare Conference

Business Wire February 27, 2026

Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

Business Wire February 26, 2026

Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)

Business Wire February 24, 2026

U.S. FDA Approves Novocure's Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer

Business Wire February 11, 2026

Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update

Business Wire January 12, 2026

Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference

Business Wire December 22, 2025

Novocure Appoints Company President Frank Leonard as Chief Executive Officer

Business Wire December 1, 2025

Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference

Business Wire November 26, 2025

Novocure to Participate in 2025 Jefferies Global Healthcare Conference

Business Wire November 12, 2025

Novocure Reports Third Quarter 2025 Financial Results

Business Wire October 30, 2025

Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress

Business Wire October 15, 2025

Novocure to Report Third Quarter 2025 Financial Results

Business Wire October 1, 2025

Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting

Business Wire September 29, 2025

Novocure's Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)

Business Wire September 15, 2025

Novocure Announces Upcoming Investor Events

Business Wire August 28, 2025

Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain

Business Wire August 25, 2025

Podcasts